Melatonin may reduce nighttime agitation for some people with dementia, which can make sundowning easier for caregivers to manage. Strong trial evidence is still weak, so expert guidelines do not recommend it as a first step. Sundowning means increased confusion, agitation, anxiety, pacing or trouble sleeping from dusk through night. It often peaks when tired caregivers need a break, according to the Alzheimer's Association guide to sleep issues and sundowning.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What small studies found
- Why larger reviews urge caution
- What should caregivers try first?
- How to discuss melatonin with a clinician
What small studies found
In an open 21-day pilot, 7 of 10 dementia patients with sleep disorders took 3 mg melatonin at bedtime. Nighttime agitation decreased and sleep onset became less variable. In a longer retrospective study, 14 Alzheimer's patients took 9 mg melatonin daily for 22 to 35 months.
Sundowning became undetectable in 12 patients and eased in 2, alongside improved sleep. These results look encouraging for families facing long nights. Both studies were very small and lacked the controls of large trials.
Why larger reviews urge caution
A 2020 Cochrane review pooled 5 randomized trials with 222 people with dementia. It found low-certainty evidence that melatonin up to 10 mg for 8 to 10 weeks may have little or no effect on major sleep measures, according to the Cochrane review of melatonin for dementia. That gap matters because small pilots often look better than larger trials.
Random assignment, blinding and varied patients tend to shrink early gains. The UK NICE NG97 guideline says melatonin should not be offered for insomnia in Alzheimer's disease. The advice appears in a systematic review of dementia behavior guidelines, described in the Frontiers in Neurology review of guidelines.
What should caregivers try first?
Most experts and NIH strongly encourage non-drug strategies first for sleep changes due mainly to Alzheimer's. Medication or supplements come later, not at the first restless evening. Keep days active, evenings calm and the bedroom dark, quiet and comfortable.
Keep wake times, meals and bedtime steady from day to day. Track what happens before bad nights. Note late caffeine, daytime naps, pain, hunger, noise, light and changes in routine.
How to discuss melatonin with a clinician
Bring the sleep diary to the visit. Ask whether melatonin fits the person's health issues, sleep pattern and other medicines.
Short-term melatonin appears safe for most people, but long-term safety is unknown. It may stay active longer in older adults and cause daytime drowsiness, so clinician review is needed, according to the NCCIH guide on melatonin safety.
- List all sleep medicines, supplements and daytime sedatives
- Ask about dose timing, morning drowsiness and falls
- Plan a short trial with clear stop rules
- Keep using bedtime routines during the trial





